REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC) Files An 8-K Regulation FD Disclosure
ITEM7.01
| REGULATION FD DISCLOSURE |
On June6, 2017, Revance Therapeutics, Inc. (the Company) will
participate at the Jefferies 2017 Global Healthcare Conference. A
copy of the slide presentation to be used by the Company in the
conference (the Presentation) is furnished as Exhibit 99.1 hereto
and is incorporated by reference herein.
The information in this Item 7.01 of this current report on Form
8-K and Exhibit 99.1 attached hereto shall not be deemed filed
for purposes of Section18 of the Securities Act of 1934, as
amended (the Exchange Act), or otherwise subject to the
liabilities of that Section, or incorporated by reference in any
filing under the Securities Act of 1933, as amended, or the
Exchange Act, except as shall be expressly set forth by specific
reference in any such filing.
| ITEM8.01 | OTHER EVENTS |
Slide 16 of the Presentation, which contains additional analysis
of data from the Companys previously reported BELMONT Study, is
incorporated herein by reference.
| ITEM9.01 | FINANCIAL STATEMENTS AND EXHIBITS |
(d) Exhibits
|
Number |
Description |
|
| 99.1 | Presentation dated June6, 2017 |
About REVANCE THERAPEUTICS, INC. (NASDAQ:RVNC)
Revance Therapeutics, Inc. is a biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its TransMTS technology enables delivery of botulinum toxin type A through investigational drug product candidates, including DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical, and DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable. Its botulinum toxin-peptide complex has over two components that contribute to the performance of RT001 and RT002. Its TransMTS peptide provides the delivery across the skin and restricts the toxin molecule to the target site. Then, the botulinum toxin type A provides the mechanism of pharmacologic action and is responsible for the drug effects demonstrated in its clinical trials. Its TransMTS peptide technology serves various purposes depending on whether it is used in a topical formulation or in an injectable formulation.